More than 30 NDAs are expected in 2022. Some industry experts suggest a record 50-plus approvals in the year ahead.
The stakes are highest for emerging biopharma and biotech companies. With everything riding on only one or two breakthrough assets, it’s crucial for these companies to choose a CDMO partner with the leadership, knowledge, and bench-to-market innovation needed to shepherd their molecules into successful commercial production.
Asymchem has been making careful investments in game-changing innovations, technologies, and approaches for over two decades, building an exceptional cross-functional team and eight sites across the globe.
Find out why we are the CDMO partner with the know-how you need today and tomorrow.